Nanomedicine News

RSS

Novavax’s RSV F-Protein Nanoparticle Vaccine Candidate Evokes Polyclonal Antibody Response to Antigenic Site II

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that its RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) evoked a polyclonal antibody response to antigenic site II, the same site targeted by the monoclonal antibody palivizumab (Synagis®), resulting in protection from an RSV challenge in an animal model.

From Novavax Inc. 16 Oct 2014

Major Advance in Implementation of ETPN Nanomedicine Translation Hub

A major step in implementing the ETPN Translation Hub has been reached, with three European projects entering the finalisation stage of their EU Grant Agreements. The project ENATRANS is for networking of SMEs in the nano-biomedical sector and supporting the SMEs with getting their products from the laboratory phase to the clinical applications.

16 Oct 2014

Anticancer Nanomedicines Have an Optimal Particle Size

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. Understanding the interdependency of physiochemical properties of nanomedicines, in correlation to their biological responses and functions, is crucial for their further development of as cancer-fighters.

16 Oct 2014

Novavax Begins Enrollment in Phase 2 Clinical Trial of RSV F Nanoparticle Vaccine

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy elderly subjects.

From Novavax Inc. 15 Oct 2014

Enhanced Red-Emission Nanoparticles Combined with Photodynamic Drug Therapy Kills Malignant Cells

An international group of scientists led by Gang Han, PhD, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.

15 Oct 2014

Nano-Optics Researchers Develop Light-Based Sensor for Blood Analysis

The development is based on optical principles and provides precision and allows saving vital time for the patient.

15 Oct 2014

UCI Receives NSF Grant to Further Develop Nano-Optical Sensor for Detecting Infection in Breath

Imagine a low-cost, disposable breath analysis device that a person with cystic fibrosis could use at home along with a smartphone to immediately detect a lung infection, much like the device police use to gauge a driver's blood alcohol level.

15 Oct 2014

Alnylam Presents Clinical Data for Patisiran Phase II OLE Study for Familial Amyloidotic Polyneuropathy

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP).

15 Oct 2014

Nanoscale DNA Cocoons Target Cancer Cells

Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale “cocoons” made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

14 Oct 2014

Onxeo Receives Second Payment from BPIFrance for Support of Nano Innovation for Cancer Consortium

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, today announces the second payment of €1.25 million from BPIFrance (ex OSEO) as a part of the funding granted to support the NICE (Nano Innovation for Cancer) consortium.

13 Oct 2014

Nanomedicine News

Novavax’s RSV F-Protein Nanoparticle Vaccine Candidate Evokes Polyclonal Antibody Response to Antigenic Site II

Major Advance in Implementation of ETPN Nanomedicine Translation Hub

Anticancer Nanomedicines Have an Optimal Particle Size

Novavax Begins Enrollment in Phase 2 Clinical Trial of RSV F Nanoparticle Vaccine

Enhanced Red-Emission Nanoparticles Combined with Photodynamic Drug Therapy Kills Malignant Cells

Nano-Optics Researchers Develop Light-Based Sensor for Blood Analysis

UCI Receives NSF Grant to Further Develop Nano-Optical Sensor for Detecting Infection in Breath

Alnylam Presents Clinical Data for Patisiran Phase II OLE Study for Familial Amyloidotic Polyneuropathy

Nanoscale DNA Cocoons Target Cancer Cells

Onxeo Receives Second Payment from BPIFrance for Support of Nano Innovation for Cancer Consortium

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

Biochar-Modified Titanium Dioxide Nanocomposites for Enhanced Water Treatment

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting